Helsinki gemfibrozil trial

9 mmol/L (111 mg/dL), were randomized to gemfibrozil 1200 mg/d or placebo and were followed up for 5 years. These include the Helsinki Heart Study, 17 the only other large clinical end point trial that has shown a significant benefit of increasing HDL-C

2024-03-19
    Imitrex and metoprolol
  1. | Semantic Scholar DOI: 10
  2. 84; P < 0
  3. These subjects were excluded from the primary study
  4. 7
  5. N Engl J Med
  6. 2%) in the gemfibrozil group and 43 (2
  7. 9%) in the gemfibrozil group and 83 (4
  8. 1%) in the placebo group; including the 3
  9. , 1990; Miller et al
  10. 2%) in the gemfibrozil group and 43 (2
  11. 9%) in the gemfibrozil group and 83 (4
  12. 1%) in the group Abstract
  13. 2%) in the gemfibrozil group and 43 (2
  14. 5‐year follow‐up
  15. 2%) in the gemfibrozil group and 43 (2
  16. This was a controlled primary prevention trial to test the
  17. 84; P < 0
  18. To secure
  19. 1%) in the placebo group; including the 3